| Filed On | Filing |
|---|---|
| 21 Nov 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +2 more
Following the Expiration Time, in accordance with the Purchase Agreement, Buyer commenced a subsequent offering period (the “Subsequent Offering Period”) in accordance with Rule 14d-11 promulgated under the Securities Exchange Act of 193... |
| 13 Nov 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Changes in Control of Registrant +1 more
UTRECHT, The Netherlands, and PHILADELPHIA, – November 13, 2025, (GLOBE NEWSWIRE) –LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced that 22,877,463 of LAVA’s common shares, representing approximately 87% of LAVA’s outstandi... |
| 07 Nov 2025 |
8-K: Submission of Matters to a Vote of Security Holders
LAVA Therapeutics N.V., a Dutch public limited liability company (naamloze vennootschap) (the “Company”), held an extraordinary general meeting of shareholders (the “EGM”) on Friday, November 7, 2025, at 2:00 p.m., Central European Summe... |
| 17 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
RE: Share Purchase Agreement – Resolution of Dispute Notice / Amendment to Purchase Agreement |
| 02 Oct 2025 |
8-K: Other Events
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. |
| 30 Sep 2025 |
8-K: Other Events
Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced acquisition in the fourth quarter of 2025. |
| 14 Aug 2025 |
8-K: Regulation FD Disclosure; Other Events
Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and unpartnered programs |
| 04 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
________________________________________________________________ |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2025, LAVA Therapeutics N.V. (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”). A total of 16,335,339 common shares were present or represented by proxy at the Annual Meeting, representing... |
| 23 May 2025 |
8-K: Changes in Registrant's Certifying Accountant
We have read the statements made by LAVA Therapeutics N.V. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of LAVA Therapeutics N.V. dated May 20, 2025. We... |
| 28 Mar 2025 |
8-K: Results of Operations and Financial Condition
Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266 |
| 28 Feb 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On February 27, 2025, LAVA Therapeutics N.V. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s... |
| 25 Feb 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
Advisor engaged in evaluating strategic options to maximize shareholder value |
| 02 Jan 2025 |
8-K: Regulation FD Disclosure
Effective January 1, 2025, LAVA Therapeutics N.V. (the “Company”) will begin to file periodic reports and registration statements on U.S. domestic issuer forms with the U.S. Securities and Exchange Commission (the “Commission”), which ar... |
Loading...